Cowen & Co. Maintains Their Hold Rating on Regeneron (REGN)


Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Regeneron (NASDAQ: REGN) today and set a price target of $385. The company’s shares opened today at $364.48.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 11.1% and a 53.2% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

Regeneron has an analyst consensus of Hold, with a price target consensus of $387.50, representing a 6.3% upside. In a report issued on August 3, Robert W. Baird also downgraded the stock to Hold with a $405 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $505.49 and a one-year low of $281.89. Currently, Regeneron has an average volume of 787.9K.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts